Bipolar androgen therapy sensitizes castration-resistant prostate cancer to subsequent androgen receptor ablative therapy is a research paper published in European Journal of Cancer (2020). On theSindex it has a DataRank of 1.2. It has been cited 47 times, with 32 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.581
From this paper's citation signal
Citation Network Contribution
0.576
From 28 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 32 citers.
National Institutes of Health
Grant: 1R01CA184012-01
National Institutes of Health
Grant: 2T32CA009071
National Institutes of Health
Grant: P30CA006973
NCI NIH HHS
Grant: R01 CA184012
NCI NIH HHS
Grant: T32 CA009071
MeSH Terms
Keywords
Additional file 1 of The clock gene BHLHE40 and atypical CCNG2 control androgen-induced cellular senescence as a novel tumor suppressive pathway in prostate cancer
Additional file 1 of The clock gene BHLHE40 and atypical CCNG2 control androgen-induced cellular senescence as a novel tumor suppressive pathway in prostate cancer
Additional file 2 of The clock gene BHLHE40 and atypical CCNG2 control androgen-induced cellular senescence as a novel tumor suppressive pathway in prostate cancer
Additional file 2 of The clock gene BHLHE40 and atypical CCNG2 control androgen-induced cellular senescence as a novel tumor suppressive pathway in prostate cancer